MAPT and dementia: This aligns with recent findings in individuals with subjective cognitive decline that showed that the A−T+ group was not more likely to progress to MCI or dementia compared with the biomarker negative group when defining “A” using Aβ PET or Aβ42 and “T” using p-tau.7,40 However, when defining A−T+ with both Aβ− and tau-PET, individuals with this profile show slightly greater risk of cognitive decline than biomarker-negative individuals.41